Guideline Updates G14: ADA Standards of Care 2025: CGM for Non-Insulin Diabetes, MASLD Treatment, and Perioperative GLP-1 Rules

The 2025 ADA Standards expand continuous glucose monitoring to non-insulin type 2 diabetes, add resmetirom for MASLD with fibrosis, ban DPP-4 plus GLP-1 combinations, and formalize perioperative GLP-1 guidance